Literature DB >> 8427289

Case report: high-dose intravenous immunoglobulin as therapy for thrombotic thrombocytopenic purpura.

M Kolodziej1.   

Abstract

Thrombotic thrombocytopenic purpura is a clinical syndrome defined by the pentad of thrombocytopenia, microangiopathic hemolytic anemia, fever, and renal and neurologic abnormalities. The pathogenesis of this syndrome remains enigmatic, though appropriate management usually involves plasma administration. The authors report on an alternative therapy, high-dose intravenous immunoglobulin, used in the patient after the failure of plasmapheresis. The implications and potential applications of this therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427289     DOI: 10.1097/00000441-199302000-00007

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  3 in total

1.  Successful treatment of recurrent thrombotic thrombocytopenic purpura with plasmapheresis and vincristine.

Authors:  S Van Gool; P Brock; P Van Laer; R Van Damme-Lombaerts; W Proesmans; M Casteels-Van Daele
Journal:  Eur J Pediatr       Date:  1994-07       Impact factor: 3.183

2.  Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide.

Authors:  Gideon Y Stein; Aliza Zeidman; Zinaida Fradin; Meir Varon; Amos Cohen; Moshe Mittelman
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

3.  Acquired idiopathic thrombotic thrombocytopenic purpura successfully treated with intravenous immunoglobulin and glucocorticoid: A case report.

Authors:  Hiro Nakao; Akira Ishiguro; Nahoko Ikoma; Kentaro Nishi; Chemin Su; Hisaya Nakadate; Mitsuru Kubota; Masaki Hayakawa; Masanori Matsumoto
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.